Agomab Therapeutics NV is a Belgium-based company. The Company is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The Company also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.
äŒæ¥ã³ãŒãAGMB
äŒç€ŸåAgomab Therapeutics NV
äžå Žæ¥Feb 06, 2026
æé«çµå¶è²¬ä»»è
ãCEOãKnotnerus (Tim)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«Feb 06
æ¬ç€Ÿæåšå°Posthoflei 1/6
éœåž
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœBelgium
éµäŸ¿çªå·2600
é»è©±çªå·
ãŠã§ããµã€ãhttps://agomab.com/
äŒæ¥ã³ãŒãAGMB
äžå Žæ¥Feb 06, 2026
æé«çµå¶è²¬ä»»è
ãCEOãKnotnerus (Tim)